C4 Therapeutics vs Foghorn Therapeutics
C4 Therapeutics is the larger business, with $35.9m of revenue in fiscal 2025 against $30.9m for Foghorn Therapeutics (1.2 times as much). Foghorn Therapeutics grew faster (36.8% against 1.0%). Foghorn Therapeutics kept more of each dollar of sales as profit: a net margin of -240.3% against -292.1%.
| Latest fiscal year | C4 TherapeuticsCCCC, 2025 | Foghorn TherapeuticsFHTX, 2025 |
|---|---|---|
| Revenue | $35.9m | $30.9m |
| Revenue growth | 1.0% | 36.8% |
| Net income | −$105m | −$74.3m |
| Operating margin | -320.5% | -279.5% |
| Net margin | -292.1% | -240.3% |
| Return on equity | -44.4% | — |
| Free cash flow | −$99.3m | −$86.1m |
| Cash | $74.6m | $80.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $193,000 | — |
| Employees | 104 | 106 |
| Market value | $393m | $124m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 1 sales | 0 buys, 0 sales |